We were interested in whether MDA-MB-231, which is a triple-negative breast cancer cell line having reduced expression of estrogen receptor (ER), progesterone receptor, and HER249, was susceptible to cell death upon combination exposure of paclitaxel, Atezolizumab, and NK92-CD16 cells. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.